A Study of PSB205 in Subjects With Advanced Solid Tumors
NCT ID: NCT03986606
Last Updated: 2020-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
64 participants
INTERVENTIONAL
2019-07-05
2021-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open-label Dose Escalation and Expansion Study of PSB205
Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.
Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts.
PSB205
PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PSB205
PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Inclusion of subjects with an ECOG performance status of 2 should be discussed and is at the discretion of the sponsor's medical monitor and the investigator.
* Life expectancy of ≥3 months.
* Female subjects who are not pregnant or breastfeeding, 1 year postmenopausal, or surgically sterile and males even if surgically sterilized that Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject.
* Suitable venous access for the study-required blood sampling, including PK and Pharmacodynamic sampling.
1. To be enrolled in Part 1 (Dose escalation), subjects must have:
1. Histologically confirmed diagnosis of advanced solid tumor and preferably radiographically or clinically measurable disease. Subjects with non-measurable, evaluable disease are permitted
2. One or more prior lines of therapy . No curative options and progressed on or following standard of care therapy (SOC).
2. To be enrolled in Part 2 (Dose expansion), subjects must have:
1. Histologically confirmed diagnosis of advanced solid tumor of the following types, and radiographically or clinically measurable disease, one or more prior lines of therapy, no curative options and progressed on or following SOC.
2. Squamous cell carcinomas- squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of the head and neck (HNSCC)
3. Locally advanced or metastatic gastric or gastroesophageal carcinoma
4. Advanced or metastatic renal cell Carcinoma (clear cell, papillary, other)
5. MSI-high colon carcinoma
6. Small cell lung cancer
7. Advanced urothelial cancer
8. Metastatic melanoma I. Advanced soft-tissue or bone sarcoma
Exclusion Criteria
2. Grade 3 or Grade 4 irAEs related to prior cancer immunotherapy.
3. Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression. Subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of study drug are permitted to enroll.
4. Hypertension unable to be controlled to ≤Grade 2 with medication.
5. Any condition requiring systemic treatment with corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before first dose of study drug. Corticosteroids for topical use, nasal spray, and inhaled steroids are allowed. Systemic corticosteroids for prophylaxis of contrast allergy are permitted.
6. Prior treatment with a CTLA-4 inhibitor in combination with a PD-1 or PD-L1 inhibitor.
7. Systemic anti-cancer treatment (including investigational agents). This includes radiotherapy \<2 weeks before the first dose of study drug, ≤4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T cell engaging agents; (≤8 weeks for cell-based therapy or anti-tumor vaccine) or have not recovered from acute toxic effects from prior chemotherapy and radiotherapy.
8. Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
9. Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
10. Subjects with a history of organ transplant.
11. Hepatitis B surface antigen-positive or known or suspected active hepatitis C infection.
12. Known human immunodeficiency virus (HIV) positive.
13. Subjects with any of the following cardiovascular conditions are excluded:
1. Acute myocardial infarction within 6 months before first dose of study drug.
2. Current or history of New York Heart Association Class III or IV heart failure.
3. Evidence of current uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
14. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
15. Subject has a history of alcoholism or drug abuse within the past 6 months.
16. Vaccinations within 4 weeks of first dose of study drug.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmaceutical Research Associates
OTHER
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Next Oncology
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anthony Tolcher, MD
Role: primary
MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSB205-001
Identifier Type: -
Identifier Source: org_study_id